A cancer therapy anchored on combining 2 sorts of cells into one unit shows potential in reinforcing prevailing therapies for acute myeloid leukemia (AML). The approach merges blood platelets that bear cancer medications with stem cells that direct the platelets where leukemia starts, that is, into bone marrow.
Scientists discovered that when administered into mice with AML, this combination therapy stopped the disease from growing any more. Of the mice that obtained the therapy, 87.5% were cured within 80 Days following the administration of combination cells. Also, those mice were all resilient to leukemia cells that were re-administrated 2 months subsequent to the 80-day episode.
Zhen Gu, a bioengineering professor at the UCLA Samueli School of Engineering, stated the technique can be utilized together with other treatments, such as stem cell treatment and chemotherapy, to enhance their efficiency. Gu stated the approach would have to be validated and permitted in human clinical trials prior to it can be integrated into treatments for leukemia patients.
The blood platelets are utilized in the combined cells to carry immunotherapy drugs known as checkpoint inhibitors (a drug known as a PD-1 antibody was used in this existing study), which look for cancer cells and deactivate their defenses. After this happens, the immune system of the body can recognize and wipe out the cancer cells. The 2nd component of the 2-cell blend is blood stem cells, or hematopoietic stem cells, which can locate their path into the bone marrow via particular chemical signals.
On the other end, according to a new study, a novel method can potentially enhance the success of ovarian cancer treatment. Rather than devastating blood supply of a tumor, a first-ever University of Guelph research has established that opening up the vessels is more efficient when taking fighting ovarian cancer into consideration. This is because open vessels offer a clear route for treatment to target the tumor.